Compositions and methods for inhibiting expression of the lect2 gene
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsGREGORY HINKLE, HUILEI XU
Life of this patent
Estimating the term…
Abstract
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
Claims32
(canceled)
A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, which antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from one of the antisense sequences listed in Tables 2 and 3.
The dsRNA of claim 4, wherein said dsRNA comprises at least one modified nucleotide.
-7. (canceled)
-10. (canceled)
(canceled)
-16. (canceled)
-27. (canceled)
-42. (canceled)
-50. (canceled)
(canceled)
-57. (canceled)
-63. (canceled)
-67. (canceled)
Dependencies are inferred from the claim text.